September 28, 2023
Senju Pharmaceutical said on September 27 that its biosimilar version of the ophthalmic vascular endothelial growth factor (VEGF) inhibitor Lucentis (ranibizumab) has obtained an additional indication of macular edema secondary to retinal vein occlusion. The product, Ranibizumab BS Intravitreal Injection...read more